Trials · for clinicians

Trial briefs, October 2026: approvals, breast, GU, gynae, myeloma and HER2 rulebook

10/10/2026 · 17 min read · updated 26 Oct 2026

Bottom line

Endpoints, arms and key numbers exactly as posted in two X threads (8 and 10 Oct 2026). Read the primary source before changing practice.

Single-topic, telegraphic briefs. Numbers are as posted in the source threads; cross-trial comparison is not valid.

October 2026 oncology updates

ATOMIC: ADJUVANT IO IN COLON CANCER

🟢 FDA approval: 8 October 2026. Resected stage III dMMR colon cancer: Atezolizumab + fluoropyrimidine/oxaliplatin. 📊 ATOMIC, n=712:

3-year DFS: 86.3% vs 76.2%
HR 0.50; 95% CI 0.35–0.73
Absolute DFS difference: 10.1 percentage points Trial schedule: 6 months atezolizumab + mFOLFOX6 → 6 months atezolizumab alone. ⚠️ Grade 3–4 adverse events: 84.1% vs 71.9%. 🔎 Clinical implication: establish MMR/MSI status before the adjuvant discussion. This indication concerns stage III dMMR disease; extrapolation to pMMR or stage II disease requires separate evidence.

Source: Dr. Senthil Kumar on X, 2026-10-10

HER2CLIMB-05: MAINTENANCE INTENSIFIES

🟢 FDA approval: 7 October 2026. Tucatinib + trastuzumab + pertuzumab after induction for unresectable locally advanced/metastatic HER2+ breast cancer. 📊 Randomised trial, n=654:

Median PFS: 24.9 vs 16.3 months
HR 0.64; 95% CI 0.51–0.80
OS immature Eligibility matters: No progression after 4–8 cycles of taxane + trastuzumab + pertuzumab; patients with or without brain metastases were eligible. 💊 Tucatinib: 300 mg twice daily. Endocrine therapy was permitted for HR+ disease. ⚠️ Hepatotoxicity, diarrhoea and creatinine elevation require attention. This trial tested maintenance after THP induction. It does not answer every contemporary first-line sequencing question.

Source: Dr. Senthil Kumar on X, 2026-10-10

ESR1: MOLECULAR PROGRESSION BEFORE SCAN PROGRESSION

🟢 Earlier development: FDA accelerated approval of camizestrant + a CDK4/6 inhibitor on 4 September 2026. SERENA-6: ER+/HER2− advanced breast cancer, receiving first-line AI + CDK4/6 inhibition for ≥6 months, with emerging ctDNA ESR1 mutation and no radiological progression. 📊 n=315:

Median PFS: 16.0 vs 9.2 months
HR 0.44
OS immature Strategy: Switch the AI to camizestrant while continuing the CDK4/6 inhibitor. ⚠️ QTc interactions and bradycardia matter. The European Guardant360 CDx announcement concerns diagnostic access. The clinical question remains precise: when should molecular resistance trigger an endocrine switch?

Source: Dr. Senthil Kumar on X, 2026-10-10

NRG-BR002: ABLATION DOES NOT AUTOMATICALLY MEAN BETTER SURVIVAL

🟡 Newly published randomised evidence in oligometastatic breast cancer. 125 eligible patients: Systemic therapy ± ablation of all metastases, predominantly SBRT. 📊 Median PFS:

No ablation: 23.0 months
Ablation: 19.5 months
HR 0.92; 95% CI 0.57–1.47 No significant OS improvement. The phase III component did not proceed. 🔎 Routine metastasis-directed ablation to improve survival is unsupported by this trial. Palliation remains a separate indication. Oligoprogression also requires its own evidence; it should not be conflated with this study population.

Source: Dr. Senthil Kumar on X, 2026-10-10

PSMADDITION: RADIOLIGANDS MOVE EARLIER

🟢 Earlier approval: 31 July 2026. 177Lu-PSMA-617 + ARPI for PSMA-positive metastatic androgen pathway modulation-naïve/sensitive prostate cancer, historically termed mHSPC. 📊 PSMAddition:

rPFS HR 0.72; 95% CI 0.58–0.90
Median rPFS not reached in either arm
OS immature PSMA PET selection is required. ADT remains foundational. ⚠️ Myelosuppression, renal toxicity, radiation precautions and treatment logistics matter. 🇮🇳 Practical appraisal must include PSMA PET access, nuclear-medicine capacity, cost and alternatives—not only the relative hazard reduction. This is an earlier approval being discussed now, not a new October approval.

Source: Dr. Senthil Kumar on X, 2026-10-10

RAMPP: CYTOREDUCTIVE PROSTATECTOMY

🟡 Randomised study, n=132: Best systemic therapy ± radical prostatectomy in prostate cancer with 1–5 bone metastases, with/without nodal involvement. 📊 Five-year outcomes:

Cancer-specific mortality: 13% vs 23%
CSM HR 0.39; 95% CI 0.16–0.98
OS: 81% vs 74%; difference not statistically significant ⚠️ Accrual stopped early. Grade ≥III surgical complications: 14%. The cancer-specific mortality signal deserves further study. It does not establish routine cytoreductive prostatectomy for contemporary metastatic practice. Separate the evidence for surgery from the evidence for prostate radiotherapy.

Source: Dr. Senthil Kumar on X, 2026-10-10

NANT: CHEMOTHERAPY-FREE NEOADJUVANT OVARIAN THERAPY?

🔵 Phase II, single-arm NANT: Eight weeks of niraparib in initially unresectable HRD+ high-grade serous ovarian cancer.

Treated: 67
Response-evaluable: 48
ORR: 30/48 = 62.5%
Operated: 40
R0 resection: 32/40 = 80% ⚠️ These are different denominators. Grade ≥3 treatment-related toxicity was substantial. Crucial counterpoint: Randomised OPAL cohort C, n=36, reported ORR 31.6% with niraparib vs 70.6% with platinum–taxane and closed for futility. NANT generates a research hypothesis. It does not justify replacing standard platinum–taxane neoadjuvant chemotherapy.

Source: Dr. Senthil Kumar on X, 2026-10-10

FRα ADCS: THE OVARIAN PIPELINE EXPANDS

🔵 Sofetabart mipitecan, LY4170156: An investigational FRα-targeting antibody–drug conjugate. Its first-in-human programme evaluates safety, dose optimisation and preliminary efficacy. The programme has also advanced to phase III FRAmework-01, including comparisons with chemotherapy or mirvetuximab in platinum-resistant disease. Questions for the eventual dataset:

Activity after prior mirvetuximab?
Dependence on FRα expression?
Payload-related toxicity?
Durable responses across resistant subgroups? Breakthrough Therapy designation supports development; it does not establish marketing approval. Avoid importing mirvetuximab’s eligibility criteria or toxicity profile into a different ADC.

Source: Dr. Senthil Kumar on X, 2026-10-10

EXCALIBER-RRMM: BIG PFS SIGNAL, REAL TOXICITY

🟡 Phase III topline update, 8 October: Iberdomide + daratumumab + dexamethasone vs DVd. 📊 Confirmatory cohort, n=800:

Median PFS: 42 vs 20 months
HR 0.49; reported p<0.000001 Published primary MRD analysis:
MRD-negative CR: 41% vs 21%
Grade 3–4 neutropenia: 84% vs 11%
Grade 3–4 infection: 39% vs 22% 🔎 Eligibility matters: 1–2 prior lines; anti-CD38-refractory and bortezomib-refractory disease were excluded. A compelling efficacy signal with substantial supportive-care requirements. Do not extrapolate directly to daratumumab-refractory myeloma.

Source: Dr. Senthil Kumar on X, 2026-10-10

FRAIL MYELOMA & THE “CURE” QUESTION

🟡 Updated MAIA frailty analysis: D-Rd vs Rd in transplant-ineligible NDMM. Frail subgroup:

Median PFS: 52.2 vs 30.4 months
HR 0.64
OS HR 0.79; 95% CI 0.58–1.06 PFS benefit persists. The frail-subgroup OS difference was not statistically significant; frailty was assessed retrospectively. 🔵 Earlier CARTITUDE-1 follow-up: 32/97 patients remained progression-free for ≥5 years after cilta-cel, without maintenance or subsequent myeloma therapy. Serial MRD and imaging confirmation was reported in a 12-patient subset. Remarkable treatment-free remission deserves recognition. “Cure” requires more mature evidence and should not be inferred from selected long-term survivors.

Source: Dr. Senthil Kumar on X, 2026-10-10

BISPECIFICS MOVE EARLIER

🟡 CELESTIMO, phase III: Mosunetuzumab + lenalidomide vs rituximab + lenalidomide in R/R follicular lymphoma after ≥1 prior line. The September sponsor announcement reported a positive PFS endpoint. Numerical effect size and detailed safety are needed before ranking its clinical value. 🔵 First-line DLBCL phase II, n=41: Glofitamab + pola-R-CHP.

Best CR: 95%
24-month PFS: 95%
CRS: 4 patients, all grade 1
No reported ICANS Glofitamab started in cycle 3 after initial chemotherapy. Promising schedule and activity—but a small single-arm cohort cannot establish superiority over standard first-line therapy.

Source: Dr. Senthil Kumar on X, 2026-10-10

ADDED UPDATE: FIRST-LINE CLL

🟢 FDA approval: 2 October 2026. Pirtobrutinib for previously untreated CLL/SLL with no known del(17p). 📊 BRUIN CLL-313, n=282: Pirtobrutinib vs bendamustine–rituximab.

Median PFS: not estimable vs 33.5 months
HR 0.20; 95% CI 0.11–0.37
OS immature 💊 Pirtobrutinib: 200 mg once daily. ⚠️ Infections, bleeding, cytopenias and arrhythmias remain relevant. Comparator caveat: Superiority to BR does not establish superiority to modern covalent BTK inhibitors or fixed-duration venetoclax-based therapy. The original social-media sweep missed a clinically important CLL development.

Source: Dr. Senthil Kumar on X, 2026-10-10

ADDED UPDATE: POST-IO RCC

🟢 FDA approval: 24 September 2026. Belzutifan + lenvatinib for advanced RCC with a clear-cell component after PD-1/PD-L1 therapy. 📊 LITESPARK-011, n=747: Combination vs cabozantinib.

Median PFS: 14.6 vs 10.6 months
PFS HR 0.74
ORR: 53% vs 40%
Median OS: 33.7 vs 28.6 months
OS HR 0.85; 95% CI 0.70–1.03 Final OS analysis was not statistically significant. ⚠️ Monitor anaemia and hypoxia from belzutifan, alongside hypertension, proteinuria and other lenvatinib toxicities. Correction to the watch-list: LITESPARK-011 already has regulatory outcome data; it is not simply awaiting an ESMO headline.

Source: Dr. Senthil Kumar on X, 2026-10-10

ADDED UPDATES: LUNG & BILIARY CANCER

🟢 9 September: Sevabertinib’s FDA accelerated indication expanded to include untreated advanced non-squamous NSCLC with HER2/ERBB2 TKD activating mutations. SOHO-01 untreated cohort, n=69:

ORR 75%
Among responders, 73% had response duration ≥6 months ⚠️ Diarrhoea, hepatotoxicity and ILD/pneumonitis. HER2 mutation is a distinct biomarker from HER2 IHC expression. 🟢 23 September: Lirafugratinib approved for previously treated advanced cholangiocarcinoma with FGFR2 fusion/rearrangement. REFOCUS, n=116:
ORR 46%
Median response duration 11.8 months Trial patients were FGFR-inhibitor naïve. Monitor phosphate and ocular toxicity.

Source: Dr. Senthil Kumar on X, 2026-10-10

ctDNA MOVES FROM PROGNOSIS TO TREATMENT SELECTION

🟢 Earlier development: 15 May 2026. FDA approval of adjuvant atezolizumab after cystectomy for MIBC with ctDNA molecular residual disease, identified by an FDA-authorised test. 📊 IMvigor011, ctDNA-positive randomised population, n=250:

Median DFS: 9.9 vs 4.8 months
DFS HR 0.64
Median OS: 32.8 vs 21.1 months
OS HR 0.59 Signatera CDx was approved for patient selection. 🔎 The evidence concerns serially detected postoperative ctDNA-positive disease. It should not be extended automatically to ctDNA-negative patients or to every commercially available MRD assay. Biomarker selection can define who receives treatment—not merely who has higher recurrence risk.

Source: Dr. Senthil Kumar on X, 2026-10-10

MULTICANCER SCREENING: A MAJOR REALITY CHECK

🟡 NHS-Galleri full results are available—not merely a Quick Take. Randomised population: 142,250. After three screening rounds:

Primary endpoint, stage III/IV incidence across 12 prespecified cancers: IRR 1.03; 95% CI 0.92–1.14; p=0.63
Stage IV secondary endpoint: IRR 0.86; 95% CI 0.74–1.00 The primary endpoint was not met. A possible stage IV signal requires follow-up; a mortality benefit has not been established by these findings. 🔵 Natera’s 9 October MCED announcement: FDA Breakthrough Device designation. Designation ≠ approval. Test performance ≠ demonstrated screening benefit.

Source: Dr. Senthil Kumar on X, 2026-10-10

THE WATCH-LIST

ESMO Congress: Madrid, 23–27 October 2026. The supplied watch-list includes: INTerpath001 • VOLGA • ANZUP1801 • DeLLphi305 • SAFFRON • CLARITYGastric01 • MOIO • TroFuse005. These remain watch-list items here; no unverified results are being assigned to them. 🔵 Carotuximab + apalutamide: A phase II programme is confirmed. The circulated 17.7-vs-2.0-month PFS figure needs the complete primary dataset, denominators, confidence intervals and comparator context before clinical interpretation. 🤖 AI in oncology: An “augment, not replace” spotlight supplies no comparative clinical-outcome evidence. Reading rule: Population → comparator → absolute benefit → toxicity → maturity → affordability. #OncoTwitter #Oncology #PrecisionOncology #Immunotherapy #BreastCancer #ColonCancer #Myeloma #CLL #RCC #ESMO26

Source: Dr. Senthil Kumar on X, 2026-10-10

HER2 breast cancer — 2026

🚀 DESTINY-BREAST11 — ADCS ENTER NEOADJUVANT THERAPY

May 2026: a new preoperative option. 📊 DESTINY-Breast11 High-risk early HER2+ breast cancer. Phase III | n=927. Key comparison: 🔹 T-DXd ×4 cycles → THP ×4 cycles. 🔹 Dose-dense AC ×4 → THP ×4. Pathologic complete response: 🔥 67.3% vs 56.3%. Absolute improvement: 11 percentage points. p=0.003. T-DXd dose: 5.4 mg/kg IV every 3 weeks ×4 before THP. 📅 15 May 2026: FDA approved T-DXd → THP for neoadjuvant stage II–III HER2+ disease. What is NOT proven? ⚠️ Mature EFS/OS superiority is not yet established. ⚠️ Comparison was against ddAC→THP, not directly against standard TCHP. ⚠️ Greater pCR does not automatically mean greater cure probability for every individual. ⚠️ T-DXd introduces ILD/pneumonitis risk. 🎯 Practical implication: Discuss T-DXd→THP as an approved neoadjuvant option in eligible stage II–III disease where available. Do not claim TCHP is obsolete. A new regimen has arrived. The optimal patient remains a clinical question.

Source: Dr. Senthil Kumar on X, 2026-10-08

⚔️ NON-pCR: T-DM1 OR T-DXd?

Residual invasive HER2+ cancer after neoadjuvant treatment is a therapeutic decision point. Not all residual disease is equal. 📊 KATHERINE n=1,486 | Residual invasive HER2+ disease. T-DM1 3.6 mg/kg every 3 weeks ×14 vs trastuzumab. At 8.4-year median follow-up:

7-year IDFS: 80.8% vs 67.1%.
7-year OS: 89.1% vs 84.4%.
OS HR 0.66. T-DM1 established post-neoadjuvant escalation with proven survival benefit. THEN CAME: 📊 DESTINY-Breast05 n=1,635 | High-risk residual invasive HER2+ disease. T-DXd 5.4 mg/kg vs T-DM1 3.6 mg/kg, every 3 weeks, up to 14 cycles. 🔥 3-year IDFS: 92.4% vs 83.7%. 🔥 HR 0.47; p<0.0001. 📅 15 May 2026: FDA approved adjuvant T-DXd for residual invasive HER2+ disease after neoadjuvant trastuzumab ± pertuzumab and taxane-based therapy. How to choose? ✅ High-risk residual disease, adequate pulmonary reserve, access to T-DXd → strongly consider T-DXd. ✅ Limited residual burden, substantial ILD risk or affordability concerns → T-DM1 remains a robust option. ⚠️ DESTINY-Breast05 enrolled a high-risk population. FDA indication is broader than the precise trial population. ⚠️ T-DXd OS data remain immature. 🎯 Non-pCR now has two evidence-based ADC options. The decision is efficacy versus toxicity, not simply newest versus oldest.

Source: Dr. Senthil Kumar on X, 2026-10-08

🌍 FIRST-LINE HER2+ METASTATIC BREAST CANCER — 2026

For over a decade, THP dominated first line. Now there are TWO major evidence-based approaches. 📊 CLEOPATRA Docetaxel + trastuzumab + pertuzumab (THP). Median OS: 57.1 vs 40.8 months. HR 0.69 against docetaxel–trastuzumab. 💊 Docetaxel usually ≥6 cycles if tolerated, followed by HP maintenance until progression. 📊 DESTINY-Breast09 T-DXd + pertuzumab vs THP. n=1,157 across 3 randomised arms. 🔥 Median PFS: 40.7 vs 26.9 months. 🔥 HR 0.56; p<0.0001. 🔥 ORR: 87% vs 81%. OS immature at primary PFS analysis. 📅 FDA first-line approval: 15 December 2025. 📘 ESMO 2026: Both THP and T-DXd + pertuzumab are recommended [I,A]. CHOOSING 1L 🔹 T-DXd + P: Major PFS benefit; consider when access and pulmonary safety permit. 🔹 THP: Mature OS data, established maintenance pathways and an ADC-free first-line approach. ⚠️ T-DXd requires vigilance for ILD. It is not a short, fixed six-cycle induction like docetaxel. ⚠️ There is no head-to-head proof that 1L T-DXd→later HER2 therapy improves OS versus THP→2L T-DXd. 🎯 ESMO recommendation ≠ a mandate to abandon THP. Choose the full therapeutic sequence, not only the longest first-line PFS.

Source: Dr. Senthil Kumar on X, 2026-10-08

💎 HER2+ MAINTENANCE — PATINA VS HER2CLIMB-05

After 4–8 cycles of taxane + HP, no progression. What next? It is no longer simply indefinite trastuzumab–pertuzumab. 📊 PATINA HR+/HER2+ metastatic breast cancer after induction therapy. HP + endocrine therapy ± palbociclib. 🔥 Median PFS: 44.3 vs 29.1 months. 🔥 HR 0.75; p=0.02. 💊 Palbociclib 125 mg daily, days 1–21 every 28 days, with appropriate dose modifications. ⚠️ Grade 3/4 neutropenia is common. 📊 HER2CLIMB-05 n=654 | HER2+ MBC, any HR status. After 4–8 cycles of taxane + HP, without progression: HP + tucatinib vs HP + placebo. 🔥 Median maintenance-phase PFS: 24.9 vs 16.3 months. 🔥 HR 0.64; p<0.0001. 💊 Tucatinib 300 mg twice daily continuously. 📅 7 October 2026: FDA approved tucatinib + HP maintenance after induction treatment. PRACTICAL SELECTION ✅ HR+/HER2+: HP + endocrine therapy remains a foundation. Palbociclib-based or tucatinib-based escalation can be discussed according to evidence, availability and toxicity. ✅ HR−/HER2+: HP ± tucatinib is relevant; PATINA does not apply. ⚠️ NEVER directly compare the 44.3-month PATINA PFS against 24.9-month HER2CLIMB-05 PFS. Different populations. Different designs. Different risk profiles. 🎯 The next frontier is personalised maintenance, not necessarily indefinite chemotherapy.

Source: Dr. Senthil Kumar on X, 2026-10-08

⚔️ SECOND-LINE HER2+ MBC — WHAT AFTER FIRST-LINE?

Sequencing must now be based on prior ADC exposure. SCENARIO A: Progression after first-line THP. 📊 DESTINY-Breast03 T-DXd vs T-DM1.

Median PFS: 29.0 vs 7.2 months.
HR 0.30.
Median OS: 52.6 vs 42.7 months.
OS HR 0.73.
ORR: 78.9% vs 36.9%. 🎯 T-DXd 5.4 mg/kg q3w is preferred when available and appropriate. SCENARIO B: Progression after first-line T-DXd + pertuzumab. ⚠️ No adequately validated phase III standard sequence specifically after first-line T-DXd. Options according to prior exposure, CNS disease and availability: 🔹 Tucatinib + trastuzumab + capecitabine. 🔹 T-DM1 if not previously received. 🔹 Trastuzumab with an alternative chemotherapy partner. 🔹 Neratinib–capecitabine or lapatinib–capecitabine in selected circumstances. 🔹 Clinical trial whenever available. SCENARIO C: Early metastatic relapse after adjuvant T-DM1/T-DXd. Do NOT mechanically apply a trastuzumab-naive metastatic sequence. Reassess treatment-free interval, cardiac/pulmonary reserve, prior toxicities and CNS involvement. 🎯 The 2026 problem: We have excellent drugs. But the optimal sequence after early ADC exposure remains incompletely defined. Drug availability is not the same as sequencing evidence.

Source: Dr. Senthil Kumar on X, 2026-10-08

🧠 HER2+ BRAIN METASTASES — A DIFFERENT SEQUENCING PROBLEM

HER2+ breast cancer has a substantial propensity for CNS relapse. But every brain metastasis does NOT require a new systemic regimen. SCENARIO 1: Isolated intracranial progression, extracranial disease controlled. ✅ SRS or surgery where appropriate. ✅ Continue effective systemic HER2 therapy if extracranial control persists. SCENARIO 2: Multiple/progressive brain lesions requiring systemic CNS-active treatment. 📊 HER2CLIMB Tucatinib + trastuzumab + capecitabine. Among patients with brain metastases: 🔥 1-year CNS-PFS: 40.2% vs 0%. 🔥 Intracranial ORR in measurable active disease: 47.3% vs 20.0%. 🔥 Median OS: 18.1 vs 12.0 months in the brain-metastasis subgroup analysis. 💊 Tucatinib 300 mg twice daily. 💊 Capecitabine 1,000 mg/m2 twice daily, days 1–14 q21d. 💊 Trastuzumab q3w. 📊 DESTINY-Breast12 T-DXd demonstrated substantial intracranial activity in HER2+ MBC with baseline brain metastases. ESMO 2026:

T-DXd is an important preferred systemic option after prior taxane–trastuzumab.
Tucatinib triplet is particularly relevant following T-DXd progression. ⚠️ Symptomatic mass effect or neurological deterioration requires urgent CNS assessment and local intervention when indicated. ⚠️ Concurrent SRS and ADC administration requires caution; treatment timing should be coordinated. 🎯 Think in two compartments: The brain may progress while the body remains controlled. Treat the compartment that is failing.

Source: Dr. Senthil Kumar on X, 2026-10-08

🇮🇳 HER2 BREAST CANCER — 2026 CLINICAL RULEBOOK

EARLY DISEASE ✅ pT1aN0: individualise chemotherapy–trastuzumab; omission reasonable in selected low-risk patients. ✅ pT1b/cN0: consider/adopt weekly paclitaxel–trastuzumab according to risk. ✅ cT2 or N+: prefer neoadjuvant HER2-directed combination therapy. ✅ pCR: complete planned anti-HER2 treatment. ✅ Residual invasive disease: T-DM1 or T-DXd according to evidence, risk, approval and access. METASTATIC DISEASE ✅ 1L: THP or T-DXd + pertuzumab. ✅ Following taxane–trastuzumab: T-DXd preferred if not previously exposed. ✅ Brain metastases: consider T-DXd and/or tucatinib triplet according to line, CNS status and prior drugs. ✅ HR+/HER2-low/ultralow after endocrine progression: assess T-DXd eligibility. SAFETY RULES 🫀 Check LVEF before and during relevant HER2 therapies; interrupt or modify per agent-specific criteria. 🫁 T-DXd:

Suspected ILD → interrupt, investigate promptly.
Confirmed grade 1 → hold until resolution, adjust as indicated.
Grade ≥2 → permanently discontinue and treat appropriately. 🩸 T-DM1: monitor platelets and transaminases. 💊 Tucatinib: monitor liver enzymes, diarrhoea and drug interactions. 💊 Neratinib: prevent/manage diarrhoea aggressively. INDIA / LMIC PRIORITIES 🔹 Do not compromise curative therapy without exploring quality-assured biosimilars. 🔹 Prioritise effective, affordable adjuvant trastuzumab for eligible patients. 🔹 Avoid escalating tiny low-risk tumours simply because new drugs exist. 🔹 Reassess HER2 on metastatic tissue when feasible. 🔹 Distinguish trial efficacy from local approval, affordability and realistic treatment completion. 🎯 FINAL TAKEAWAY Test precisely. Stage correctly. Select by risk. Sequence by prior exposure. HER2 care is no longer one drug for one receptor. It is a treatment pathway spanning diagnosis, cure, recurrence and resistance. #Oncology #OncTwitter #BreastCancer #HER2 #HER2Low #ADC #Trastuzumab #TDM1 #Enhertu #ESMO #NCCN

Source: Dr. Senthil Kumar on X, 2026-10-08

Sources

Educational summary, not medical advice. Opinions are labelled as such and are the author's own. Approvals and availability in India (CDSCO) may differ from the US/EU.

← Back to blog